Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (41-50 of 237) with videos related to

Pageof 24
Sort By:
The Oncologist|June 6, 2024
Harvesting information from Kaplan-Meier plots: part 1-detecting censoringAntonio Tito Fojo, Brian Labadie
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?Tito Fojo, David R Parkinson
Advances in Therapy|November 28, 2025
Letter to the Editor Regarding 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'Martin W Schoen, Tito Fojo
Clinical Breast Cancer|November 21, 2007
The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategiesTito Fojo, Helen M Coley
JNCI Cancer Spectrum|April 29, 2024
The statistical significance revolutionAlfred I Neugut, Tito Fojo
Nature Reviews. Clinical Oncology|February 24, 2016
Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvalsSusan E Bates, Tito Fojo
Cell Cycle (Georgetown, Tex.)|September 28, 2011
Taccalonolides: a microtubule stabilizer poses a new puzzle with old piecesDan L Sackett, Tito Fojo
Journal of the National Cancer Institute|April 12, 2012
Why do phase III clinical trials in oncology fail so often?Laleh Amiri-Kordestani, Tito Fojo
The Lancet. Oncology|September 30, 2021
Inappropriate censoring in Kaplan-Meier analysesTito Fojo, Richard M Simon
The Lancet. Oncology|January 14, 2016
Price, value, and the cost of cancer drugsTito Fojo, Andrew W Lo
Pageof 24

Showing results (41-50 of 237) with videos related to

Sort By:
Pageof 24
The Oncologist|June 6, 2024
Harvesting information from Kaplan-Meier plots: part 1-detecting censoringAntonio Tito Fojo, Brian Labadie
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?Tito Fojo, David R Parkinson
Advances in Therapy|November 28, 2025
Letter to the Editor Regarding 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'Martin W Schoen, Tito Fojo
Clinical Breast Cancer|November 21, 2007
The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategiesTito Fojo, Helen M Coley
JNCI Cancer Spectrum|April 29, 2024
The statistical significance revolutionAlfred I Neugut, Tito Fojo
Nature Reviews. Clinical Oncology|February 24, 2016
Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvalsSusan E Bates, Tito Fojo
Cell Cycle (Georgetown, Tex.)|September 28, 2011
Taccalonolides: a microtubule stabilizer poses a new puzzle with old piecesDan L Sackett, Tito Fojo
Journal of the National Cancer Institute|April 12, 2012
Why do phase III clinical trials in oncology fail so often?Laleh Amiri-Kordestani, Tito Fojo
The Lancet. Oncology|September 30, 2021
Inappropriate censoring in Kaplan-Meier analysesTito Fojo, Richard M Simon
The Lancet. Oncology|January 14, 2016
Price, value, and the cost of cancer drugsTito Fojo, Andrew W Lo
Pageof 24